Drug Trial Radar · NCT05054348
First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jun 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
91
Actual
Start
Sep 30, 2021
Primary completion
Apr 29, 2024
Study completion May 31, 2024
Sponsor
- Lead sponsor
- Immune-Onc TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Sep 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of the clinical trial is to learn about safety, tolerability and preliminary efficacy of IO-108 as monotherapy or in combination with a PD-1 inhibitor in patients with advanced, metastatic solid tumors, and to find a dose of IO-108 that is safe and efficacious to be tested in patients with various solid tumors.
Conditions
- Solid Tumor, Adult
Interventions
IO-108Biological
IO-108 given as monotherapy
IO-108 + pembrolizumab combination therapyBiological
IO-108 and fixed dose pembrolizumab combination therapy
IO-108 + cemiplimab combination therapyBiological
IO-108 and fixed dose cemiplimab combination therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent and serious adverse events in patients treated with IO-108 and IO-108+pembrolizumabTime frame: From first dose of IO-108 until the end of treatment which is up to 2 years from the first treatment date or disease progression whichever is earlier
- Determine MTD (maximum tolerated dose) through assessment of dose-limiting toxicities (DLT)Time frame: From the first dose of IO-108 until 21 days post-treatment
- Assess safety and tolerability of the IO-108 RP2D as monotherapy or in combination with either pembrolizumab or cemiplimab in patients with solid tumorsTime frame: From the first dose of IO-108 until the end of treatment which is up to 2 years from the first treatment or disease progression, whicheer is earlier
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
Arizona Oncology Associates, PC-HOPE (140) (USOR SITE)
Tucson, Arizona
Beverly HIlls Cancer Center (129)
Beverly Hills, California
Rocky Mountain Cancer Centers, LLP (141) (USOR SITE)
Lone Tree, Colorado
University of Florida (125)
Gainesville, Florida
Florida Cancer Specialists (134)
Lake Mary, Florida
Memorial Cancer Institute (146)
Pembroke Pines, Florida
Florida Cancer Specialists & Research Institute (103)
Sarasota, Florida
Hematology Oncology (136)
Stuart, Florida
Indiana University Melvin and Bren Simon Comprehensive Cancer Center (123)
Indianapolis, Indiana
Maryland Oncology Hematology, PA (145) (USOR SITE)
Columbia, Maryland
Karmanos Cancer Institute (126)
Detroit, Michigan
St. Vincent - Frontier Cancer Center (135)
Billings, Montana
NYU Langone Health (131)
New York, New York
Carolina BioOncology (102)
Huntsville, North Carolina
Gabrail Cancer Center (128)
Canton, Ohio
Oncology Hematology Care Clinical Trials, LLC (144) (USOR SITE)
Cincinnati, Ohio
Providence Cancer Institute (104)
Portland, Oregon
UPMC Hillman Cancer Center (105)
Pittsburgh, Pennsylvania
Texas Oncology - Austin (142) (USOR SITE)
Austin, Texas
Texas Oncology - Baylor Charles A. (143) (USOR SITE)
Dallas, Texas
MD Anderson Cancer Center (101)
Houston, Texas
Oncology Consultants, P.A. (138)
Houston, Texas
NEXT Oncology-Virginia (121)
Fairfax, Virginia
Swedish Cancer Institute (147)
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.